Cooperation to Create a new Tuberculosis Vaccine
Max Planck Institute for Infection Biology and MOLOGEN initiate development of a new tuberculosis subunit vaccine
A cooperation agreement to initiate the development of a new type of preventive DNA subunit vaccine against tuberculosis (TB) has been signed by the Max Planck Institute for Infection Biology (MPI-IB) and MOLOGEN AG in Berlin. Subunit vaccines are composed of defined molecular immunogenic modules. Under its director Prof. Dr. Stefan H. E. Kaufmann, the Department of Immunology at the MPI-IB is studying the mechanisms of host - pathogen interactions and develops novel vaccination strategies; it is amongst the leading groups in Tuberculosis immunology research world wide. MOLOGEN focuses on proprietary DNA technologies to develop treatments for non- or inadequately treatable diseases.
Max Plank Society Press Release